GeneThera, Inc. (OTCMKTS:GTHR) announced that it entered into a partnership deal, with the Hudson Robotics Inc. The primary objective of this collaboration agreement is to work on the development of the latest and the next generation Integrated Automated Robotic Systems for animal diagnostic treatments.
Insights On The Deal:
As per the reports, IARS can be used as the molecular diagnostic platform for the testing of Paratuberculosis and Tuberculosis in animals. There are various health solutions available for human diseases, but not many, when it comes to animals; hence, this collaboration of GTHR and Hudson Robotics can prove to be a game-changing step. According to the terms and conditions of the deal, Hudson Robotics Inc. will get the rights of 10% equity ownership in GTHR.
The management of GTHR is excited to enter into this collaboration agreement. Dr. Tony Milici, CEO of GeneThera, Inc. (OTCMKTS:GTHR), stated that it was a turning point for his company. There is no other firm in the world, which has more expertise than Hudson Robotics Inc. in the field of Integrated Automation Robotic Systems; hence, GTHR will achieve its objective without any difficulty. The robotic and molecular diagnostic platform of both the companies is probably the best-designed platform for animal diagnostic. If everything goes fine, then this advanced system will completely change the way animal testing is done in the near future.
Management of GeneThera, Inc. (OTCMKTS:GTHR) is confident that it will be able to establish world-class IARS laboratories equipped with high-end technology all around the globe, with the help of Hudson Robotics Inc. These IARS laboratories will not only make available the latest treatments, but also elevate the standards of animal diagnostic. Both the companies are likely to start working together on some of the new animal diagnostic treatments in the near future, details of which have not been disclosed yet.